Sarepta Therapeutics (SRPT) Licenses Galgt2 Gene Therapy Program from Nationwide Children’s Hospital – StreetInsider.com
|
Sarepta Therapeutics (SRPT) Licenses Galgt2 Gene Therapy Program from Nationwide Children's Hospital
StreetInsider.com The experimental program explores the potential surrogate gene therapy approach to Duchenne muscular dystrophy. As a “surrogate gene therapy approach”, the gene therapy looks to induce genes that make proteins that can perform a similar function as … |
